Jekyll and Hide

References

• Clanet M. Jean-Martin Charcot. 1825 to 1893. Int MS J 2008; 15:59 - 61; PMID: 18782501
   PubMedGoogle Scholar
• Society NMS. What we know about MS. national MS Society 2012.
   Google Scholar
• Grant JL, Ghosn EE, Axtell RC, Herges K, Kuipers HF, Woodling NS, et al. Reversal of paralysis and reduced inflammation from peripheral administration of beta-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med 2012; 4:145ra05.
   Google Scholar
• Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med 2006; 354:942 - 55; http://dx.doi.org/10.1056/NEJMra052130; PMID: 16510748
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278 - 85; http://dx.doi.org/10.1056/NEJM199801293380502; PMID: 9445407
   PubMed Web of Science ®Google Scholar
• Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120:393 - 9; http://dx.doi.org/10.1093/brain/120.3.393; PMID: 9126051
   PubMed Web of Science ®Google Scholar
• Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron 2006; 49:489 - 502; http://dx.doi.org/10.1016/j.neuron.2006.01.022; PMID: 16476660
   PubMed Web of Science ®Google Scholar
• Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 1989; 24:173 - 82; http://dx.doi.org/10.1016/0165-5728(89)90115-X; PMID: 2808689
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 2006; 12:1005 - 15; PMID: 16960575
   PubMed Web of Science ®Google Scholar
• Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989; 86:7611 - 5; http://dx.doi.org/10.1073/pnas.86.19.7611; PMID: 2529544
   PubMed Web of Science ®Google Scholar
• Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 1992; 89:10016 - 20; http://dx.doi.org/10.1073/pnas.89.21.10016; PMID: 1438191
   PubMed Web of Science ®Google Scholar
• Monsonego A, Weiner HL. Immunotherapeutic approaches to Alzheimer’s disease. Science 2003; 302:834 - 8; http://dx.doi.org/10.1126/science.1088469; PMID: 14593170
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297:353 - 6; http://dx.doi.org/10.1126/science.1072994; PMID: 12130773
   PubMed Web of Science ®Google Scholar
• Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer’s disease. Nat Rev Immunol 2006; 6:404 - 16; http://dx.doi.org/10.1038/nri1843; PMID: 16639431
   PubMed Web of Science ®Google Scholar
• Proft J, Weiss N. A protective mutation against Alzheimer disease?. Commun Integr Biol 2012; 5:301 - 3; http://dx.doi.org/10.4161/cib.21799; PMID: 23060947
   PubMedGoogle Scholar
• Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990; 8:579 - 621; http://dx.doi.org/10.1146/annurev.iy.08.040190.003051; PMID: 2188675
   PubMed Web of Science ®Google Scholar
• Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010; 16:406 - 12; http://dx.doi.org/10.1038/nm.2110; PMID: 20348925
   PubMed Web of Science ®Google Scholar
• Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13:139 - 45; http://dx.doi.org/10.1038/nm1551; PMID: 17290272
   PubMed Web of Science ®Google Scholar
• Esler WP, Wolfe MS. A portrait of Alzheimer secretases--new features and familiar faces. Science 2001; 293:1449 - 54; http://dx.doi.org/10.1126/science.1064638; PMID: 11520976
   PubMed Web of Science ®Google Scholar
• Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005; 4:510 - 8; http://dx.doi.org/10.1038/nrd1752; PMID: 15931259
   PubMed Web of Science ®Google Scholar
• Biogen Idec and Elan Pharmaceuticals I. Biogen Idec and Elan Pharmaceuticals, Inc.. , 2012.
   Google Scholar
• Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33:91 - 101; http://dx.doi.org/10.1097/WNF.0b013e3181cbf825; PMID: 20061941
   PubMed Web of Science ®Google Scholar
• Corporation NP. . 2012.
   Google Scholar
• St George-Hyslop PH. Molecular genetics of Alzheimer’s disease. Biol Psychiatry 2000; 47:183 - 99; http://dx.doi.org/10.1016/S0006-3223(99)00301-7; PMID: 10682216
   PubMed Web of Science ®Google Scholar
• St George-Hyslop PH. Genetic factors in the genesis of Alzheimer’s disease. Ann N Y Acad Sci 2000; 924:1 - 7; http://dx.doi.org/10.1111/j.1749-6632.2000.tb05552.x; PMID: 11193785
   PubMed Web of Science ®Google Scholar
• Brindle N, George-Hyslop PS. The genetics of Alzheimer’s disease. Methods Mol Med 2000; 32:23 - 43; PMID: 21318509
   PubMedGoogle Scholar
• Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 2012; 33:1340 - 4; http://dx.doi.org/10.1002/humu.22117; PMID: 22581678
   PubMed Web of Science ®Google Scholar
• Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M. Autoantibodies against beta-amyloid are common in Alzheimer’s disease and help control plaque burden. Ann Neurol 2009; 65:24 - 31; http://dx.doi.org/10.1002/ana.21475; PMID: 19194878
   PubMed Web of Science ®Google Scholar
• Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O’Connor KC, Hafler DA, et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 2007; 448:474 - 9; http://dx.doi.org/10.1038/nature05935; PMID: 17568699
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9:448 - 52; http://dx.doi.org/10.1038/nm840; PMID: 12640446
   PubMed Web of Science ®Google Scholar
• Check E. Nerve inflammation halts trial for Alzheimer’s drug. Nature 2002; 415:462; http://dx.doi.org/10.1038/415462a; PMID: 11823817
   PubMed Web of Science ®Google Scholar
• You H, Gadotti VM, Petrov RR, Zamponi GW, Diaz P. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands. Mol Pain 2011; 7:89; http://dx.doi.org/10.1186/1744-8069-7-89; PMID: 22093952
   PubMed Web of Science ®Google Scholar